Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on: November 07,2023

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on:November 07,2023

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th

Updated on: January 04,2024

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th

Updated on:January 04,2024

Molecular delivery system developed at URI shows promise against bladder cancer

byUniversity of Rhode IslandpHLIP-ICG can locate cancerous lesions and illuminate them with a fluorescent molecule, making them potentially easier for surgeons to see and remove. Credit: URIA re

Updated on: December 17,2023

Molecular delivery system developed at URI shows promise against bladder cancer

byUniversity of Rhode IslandpHLIP-ICG can locate cancerous lesions and illuminate them with a fluorescent molecule, making them potentially easier for surgeons to see and remove. Credit: URIA re

Updated on:December 17,2023

Colorectal cancer risk remains despite modern treatment for ulcerative colitis

byKarolinska InstitutetJonas Ludvigsson, professor in the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Sweden. Credit: Gustav MårtenssonPatients with the infl

Updated on: December 20,2023

Colorectal cancer risk remains despite modern treatment for ulcerative colitis

byKarolinska InstitutetJonas Ludvigsson, professor in the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Sweden. Credit: Gustav MårtenssonPatients with the infl

Updated on:December 20,2023

Advancing gene therapy for skin cancer

by Federica Giannelli,University of SaskatchewanStudent Mays Al-Dulaymi improves gene therapy techniques. Credit: Dave StobbeOne of the deadliest skin cancers, melanoma may be caused by overexpo

Updated on: December 18,2023

Advancing gene therapy for skin cancer

by Federica Giannelli,University of SaskatchewanStudent Mays Al-Dulaymi improves gene therapy techniques. Credit: Dave StobbeOne of the deadliest skin cancers, melanoma may be caused by overexpo

Updated on:December 18,2023

Women with elevated breast cancer risk could see mortality benefit from estrogen-blocking drugs

byGeorgetown University Medical CenterCredit: Unsplash/CC0 Public DomainWhile it has long been recognized that drugs that block the cancer-promoting activity of estrogen reduce risk of developin

Updated on: December 19,2023

Women with elevated breast cancer risk could see mortality benefit from estrogen-blocking drugs

byGeorgetown University Medical CenterCredit: Unsplash/CC0 Public DomainWhile it has long been recognized that drugs that block the cancer-promoting activity of estrogen reduce risk of developin

Updated on:December 19,2023

Multimodal genomic analyses predict response to immunotherapy in lung cancer patients

by Amy Mone,Johns Hopkins University School of MedicineLung cancer. Credit: Jennifer Fairman and Valsamo Anagnostou, Johns Hopkins UniversityResearchers at Johns Hopkins Kimmel Cancer Center, th

Updated on: December 20,2023

Multimodal genomic analyses predict response to immunotherapy in lung cancer patients

by Amy Mone,Johns Hopkins University School of MedicineLung cancer. Credit: Jennifer Fairman and Valsamo Anagnostou, Johns Hopkins UniversityResearchers at Johns Hopkins Kimmel Cancer Center, th

Updated on:December 20,2023

Patient-derived Organoids: Revolutionizing Cancer Research and Treatment

Updated on: November 14,2024

Patient-derived Organoids: Revolutionizing Cancer Research and Treatment

Updated on:November 14,2024

Scientists find powerhouses that fight tumours from within

In recent years doctors have turned to a new treatment for cancer, immunotherapy, which works by leveraging the body's own immune system to fight tumoursLurking deep inside some tumours are "

Updated on: December 20,2023

Scientists find powerhouses that fight tumours from within

In recent years doctors have turned to a new treatment for cancer, immunotherapy, which works by leveraging the body's own immune system to fight tumoursLurking deep inside some tumours are "

Updated on:December 20,2023

B-Cell Lymphoma Treatment Options

B-Cell Lymphoma Treatment OptionsByJennifer Sabour, MSPublished on March 07, 2022Medically reviewed byDoru Paul, MDWhile B-cell lymphoma always originates in white blood cells

Updated on: January 28,2024

B-Cell Lymphoma Treatment Options

B-Cell Lymphoma Treatment OptionsByJennifer Sabour, MSPublished on March 07, 2022Medically reviewed byDoru Paul, MDWhile B-cell lymphoma always originates in white blood cells

Updated on:January 28,2024

Improving treatment for hairy cell leukemia

by Melissa Rohman,Northwestern UniversityCredit: Unsplash/CC0 Public DomainPatients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent respon

Updated on: December 22,2023

Improving treatment for hairy cell leukemia

by Melissa Rohman,Northwestern UniversityCredit: Unsplash/CC0 Public DomainPatients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent respon

Updated on:December 22,2023

Potential new treatment for angioimmunoblastic T-cell lymphoma

byUniversity of TsukubaCredit: AI-generated imageA type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from

Updated on: December 18,2023

Potential new treatment for angioimmunoblastic T-cell lymphoma

byUniversity of TsukubaCredit: AI-generated imageA type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from

Updated on:December 18,2023